highperformr logo

AC Immune's Overview

Total employees180
HeadquartersLausanne
Founded2003

AC Immune SA is a Swiss-based, clinical-stage biopharmaceutical company at the forefront of developing precision medicines for a wide range of neurodegenerative diseases. Leveraging its two proprietary technology platforms, SupraAntigen® (for biologics) and Morphomer® (for small molecules), AC Immune designs and develops innovative therapies targeting misfolded proteins, such as Abeta, Tau, and alpha-synuclein, which are hallmarks of conditions like Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders characterized by neuroinflammation. The company's pipeline includes diagnostic agents and therapeutic candidates, aiming to intervene early and effectively in disease progression. AC Immune is committed to advancing the understanding and treatment of these complex conditions through cutting-edge science and strategic collaborations.

Where is AC Immune's Headquarters?

HQ Function

The Lausanne headquarters serves as the central nexus for AC Immune's global operations, including cutting-edge research and development (R&D), corporate strategy, clinical trial management, and administrative functions.

Notable Features:

Being part of the EPFL (Swiss Federal Institute of Technology Lausanne) Innovation Park provides AC Immune with access to state-of-the-art infrastructure, a rich talent pool, and a collaborative ecosystem of leading research institutions and technology companies. The facilities are modern and designed to support advanced scientific research.

Work Culture:

AC Immune fosters a highly innovative, science-driven work culture. Employees often describe it as collaborative and dynamic, with a strong emphasis on scientific excellence and a shared mission to combat neurodegenerative diseases. The environment encourages critical thinking and problem-solving.

HQ Significance:

The location in Lausanne, within the EPFL Innovation Park, is significant due to its proximity to world-class academic research, a strong local biotech cluster, and Switzerland's stable and supportive environment for life sciences companies. This enhances AC Immune's R&D capabilities and global partnerships.

Values Reflected in HQ: The headquarters' location and design reflect AC Immune's core values of innovation, scientific rigor, collaboration, and a forward-looking approach to tackling complex medical challenges.

Location:

While headquartered in Switzerland, AC Immune has a significant global presence driven by its clinical development programs and collaborations. The company conducts multinational clinical trials for its therapeutic candidates across North America, Europe, and other key regions, partnering with leading research institutions and clinical research organizations (CROs). Its strategic alliances with pharmaceutical companies also extend its reach, facilitating the development and potential commercialization of its innovative treatments for neurodegenerative diseases worldwide.

Street Address:

EPFL Innovation Park, Building B

City:

Lausanne

State/Province:

Vaud

Country:

Switzerland

AC Immune's Global Presence

Buying Intent Signals for AC Immune

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Executive Team of AC Immune

As of April 2025, AC Immune' leadership includes:

Dr. Andrea Pfeifer - Chief Executive Officer
Dr. Marie Kosco-Vilbois - Chief Scientific Officer
Dr. Johannes Streffer - Chief Medical Officer
Grace G. L. Ennis - Chief Operating Officer & Chief of Staff to the CEO
Christopher Roberts - Chief Financial Officer

Investors of AC Immune

AC Immune has been backed by several prominent investors over the years, including:

Dievini Hopp BioTech holding GmbH & Co. KG
Athos Service GmbH
Van Herk Investments B.V.
Various institutional and retail investors (as a publicly traded company on NASDAQ: ACIU)

Executive New Hires/Exits in the Last 12 Months

Hire1
Exits1

In the past 12 months, AC Immune strengthened its financial leadership with the appointment of a new Chief Financial Officer, marking a key transition in its executive team.

Departures

Joerg Hornstein, Joerg Hornstein departed his role as Chief Financial Officer to pursue other opportunities.

New Appointments:

Christopher Roberts, Christopher Roberts was appointed as new Chief Financial Officer, succeeding Joerg Hornstein.

Technology (Tech Stack) used by AC Immune

Discover the tools AC Immune uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

AC Immune Email Formats and Examples

AC Immune likely employs standard corporate email formats for its employees. While specific internal structures may vary, a common professional format is 'firstname.lastname@acimmune.com'. Variations such as 'firstinitiallastname@acimmune.com' could also be in use.

first.last@acimmune.com

Format

andrea.pfeifer@acimmune.com

Example

80%

Success rate

News and media

GlobeNewswireMay 15, 2024

AC Immune Reports First Quarter 2024 Financial Results and Provides Corporate Update

AC Immune announced its Q1 2024 financial results, highlighting progress in its Alzheimer's and Parkinson's disease programs, including updates on ACI-24.060 and ACI-7104.056, and its solid cash position to fund operations....more

GlobeNewswireApril 25, 2024

AC Immune Announces First Patient Dosed in Phase 2b Trial of ACI-24.060 Anti-Amyloid Beta Vaccine Candidate in Alzheimer’s Disease

AC Immune confirmed the dosing of the first patient in its ReTain Phase 2b clinical trial evaluating ACI-24.060, an anti-amyloid beta vaccine candidate, for individuals with early Alzheimer's disease....more

GlobeNewswireMarch 7, 2024

AC Immune Reports Full Year 2023 Financial Results and Provides Corporate Update

The company reported its full-year 2023 financial results, outlining strategic priorities, clinical pipeline advancements, and anticipated milestones for its neurodegenerative disease programs....more

Highperformr’s free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including AC Immune, are just a search away.